1-methyl-4-[6-(4-o-tolyl-piperidine-1-sulfonyl)-pyridin-2-yl]-piperazine hydrochloride | 1175689-75-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-methyl-4-[6-(4-o-tolyl-piperidine-1-sulfonyl)-pyridin-2-yl]-piperazine hydrochloride
• 英文别名: 1-methyl-4-[6-[4-(2-methylphenyl)piperidin-1-yl]sulfonylpyridin-2-yl]piperazine;hydrochloride
• CAS: 1175689-75-4
• 化学式: C₂₂H₃₀N₄O₂S*ClH
• 分子量: 451.033
• InChiKey: QKFNKHUGGFZDGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.13
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  65.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-methyl-4-[6-(4-o-tolyl-piperidine-1-sulfonyl)-pyridin-2-yl]-piperazine 在 盐酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 0.5h， 以88%的产率得到1-methyl-4-[6-(4-o-tolyl-piperidine-1-sulfonyl)-pyridin-2-yl]-piperazine hydrochloride
  参考文献：
  名称：

  Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders

  摘要：

  本发明涉及一种新颖的吡啶基衍生物，其化学式如下所示：其中Y、Z、L、R1至R11、n、m、p、q、t的定义如本文所述，它们是5-HT受体配体，特别是5-HT6亚型，因此可用于治疗需要调节5-HT活性的疾病。本发明涉及包括其药用盐在内的新型吡啶基衍生物。该发明还涉及用于制备、制备中间体、含有这些化合物的药物组合物以及在治疗中枢神经系统疾病如精神分裂症中使用这些化合物的过程。

  公开号：

  US20090197859A1

文献信息

• FIG4 gene mutations in neurodegeneration
  申请人：Meisler Miriam

  公开号：US10260098B2

  公开（公告）日：2019-04-16

  The present invention relates to neurological disease, in particular to mutations in the FIG4 gene. The present invention also provides assays for the detection of variant FIG4 alleles, and assays for detecting FIG4 polymorphisms and mutations associated with disease states such as ALS.

  本发明涉及神经系统疾病，特别是 FIG4 基因的突变。本发明还提供了检测变异 FIG4 等位基因的检测方法，以及检测与 ALS 等疾病状态相关的 FIG4 多态性和突变的检测方法。
• PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS
  申请人：Pfizer Inc.

  公开号：EP2265600A1

  公开（公告）日：2010-12-29
• FIG4 GENE MUTATIONS IN NEURODEGENERATION
  申请人：Meisler Miriam

  公开号：US20090233298A1

  公开（公告）日：2009-09-17

  The present invention relates to neurological disease, in particular to mutations in the FIG4 gene. The present invention also provides assays for the detection of variant FIG4 alleles, and assays for detecting FIG4 polymorphisms and mutations associated with disease states such as ALS.
• [EN] PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS<br/>[FR] PYRIDINYLAMIDES POUR LE TRAITEMENT DES TROUBLES DU SNC ET DU MÉTABOLISME
  申请人：PFIZER

  公开号：WO2009098576A1

  公开（公告）日：2009-08-13

  The present invention relates to novel pyridinyl derivatives of Formula (I), wherein Y, Z, L, R1 through R11, n, m, p, q, t are as defined herein, that are 5-HT receptor ligands, particularly the 5-HT6 subtype, and as such are useful for treating diseases wherein modulation of 5-HT activity is desired. The present invention relates to novel pyridinyl derivatives including their pharmaceutically acceptable salts. The invention also relates to processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating diseases of the central nervous system such as schizophrenia.